Results for fibrinolytic translation from English to Maltese

ris fibrinolytic activity.
du ħin biex jieqaf id- demm (bleeding time) jew l- attivita` fibrinolitika.

stimulation of endogenous fibrinolytic potential
stimulazzjoni tal-potenzjal fibrinolitiku endoġenu

potential interactions with antithrombotic fibrinolytic agents
interazzjonijiet potenzjali ma' sustanzi fibrinolitiċi antitrombotiċi

use of fibrinolytic medicinal products for the treatment of acute ischemic stroke
l-użu ta’ prodotti mediċinali fibrinolitiċi għall-kura ta’ puplesija iskemika akuta

there is very limited experience on the use of edoxaban with dual antiplatelet therapy or fibrinolytic agents.
hemm esperjenza limitata ħafna dwar l-użu ta’ edoxaban ma’ terapija doppja kontra l-plejtlits jew mediċini fibrinolitiċi.

these agents include desirudin, fibrinolytic agents, gp iib/ iiia receptor antagonists, na
waqt trattament ta ’ tm

16 consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.
dan kien konsistenti fil- firxa ta ’ sottogruppi ta ’ pazjenti migbura skond linja bażi ta ’ karatteristiċi u t- tip ta ’ terapija fibrinolitika jew bil- heparin.

this was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.
dan kien konsistenti fil- firxa ta’ sottogruppi ta’ pazjenti migbura skond linja bażi ta’ karatteristiċi u t-tip ta’ terapija fibrinolitika jew bil-heparin.

as wound healing progresses, increased fibrinolytic activity is induced by plasmin and decomposition of fibrin to fibrin degradation products is initiated.
hekk kif il- fejqan tal- ferita javvanza, żieda fl- attività fibrinolitika hija indotta mill- plażmina u tinbeda d - dekompożizzjoni ta 'fibrina fi prodotti ta' degradazzjoni tal- fibrina.

this benefit was consistent across all prespecified subgroups including patients’ age and gender, infarct location, and type of fibrinolytic or heparin used.
dan il-benefiċċju kien konsistenti fis-sottogruppi speċifikati minn qabel li jinkludu l-età tal-pazjent, is-sess maskil jew dak femminil, il-post fejn qiegħed l- infart u t-tip ta’ sustanza fibrinolitika jew heparin użat.

or prothrombin time (pt)/ international normalised ratio (inr) tests in plasma nor bleeding time or fibrinolytic activity.
x (act) jew prothrombin time (pt) / international normalised ratio (inr) fuq il - plażma, u lanqas il -

xigris also restored endogenous fibrinolytic potential, as evidenced by a more rapid trend toward normalisation in plasminogen levels and a more rapid decline in plasminogen activator inhibitor-1 levels.
xigris radd lura wkoll il-potenzjal fibrinolitiku endoġenu, kif jidher minn tendenza aktar mgħaġġla lejn in-normalizzazzjoni fil-livelli tal-plażminoġen u tnaqqis aktar mgħaġġel fil-livelli ta’ l-inibitur-1 ta’ l-attivatur tal-plażminoġen.

the pharmaco-invasive strategy consisted of early fibrinolytic treatment with bolus tenecteplase and additional antiplatelet and anticoagulant therapy followed by angiography within 6-24 hours or rescue coronary intervention.
l-istrateġija farmakoinvażiva kienet tikkonsisti minn kura fibrinolitika bikrija b’bolus tenecteplase u terapija addizzjonali kontra l-plejtlits u antikoagulanti segwita minn anġjografija fi żmien 6-24 siegħa jew intervent koronarju ta’ salvataġġ.

when administered in conjunction with a thrombolytic (fibrin specific or non-fibrin specific) enoxaparin sodium should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy.
meta mogħti flimkien ma’ trombolitiku (speċifiku għal fibrin jew mhux speċifiku għal fibrin) enoxaparin sodium għandu jingħata bejn 15-il minuta qabel u 30 minuta wara l-bidu tat-terapija fibrinolitika.

experience with concomitant administration of anti-fibrinolytics and rfviia treatment is however limited.
madankollu, l-esperjenza bl-għoti fl- istess ħin ta’ sustanzi anti-fibrinolitiċi u l-kura b’rfviia, hi limitata.